



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-IL-13 [6A1] Standard Size Ab04494-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Fc Silent™, Kappa

**Clone Number:** 6A1

**Alternative Name(s) of Target:** IL13; Interleukin-13; P600

**UniProt Accession Number of Target Protein:** P35225

**Published Application(s):** inhibition, neutralization, SPR, ELISA

**Published Species Reactivity:** Human, Cynomolgus Monkey

**Immunogen:** The original antibody was generated by immunizing SJL mice with *E. Coli*-produced recombinant human IL-13.

**Specificity:** This antibody is specific for human IL-13. It cross-reacts with cynomolgus monkey IL-13.

**Application Notes:** The original format of this antibody (mouse IgG1) showed binding activity against *E. coli*-expressed recombinant human IL-13 in a sandwich ELISA with an  $EC_{50}$  of 0.049 and 0.039 µg/ml for human and cynomolgus IL-13. The antibody also exhibited potent binding and neutralization activities against various forms of IL-13. In inhibition assays, the antibody showed  $IC_{50}$  values of 0.165 µg/ml for blocking human IL-13 binding to IL-13R $\alpha$ 1 and 0.056 µg/ml for IL-13 binding to IL-13R $\alpha$ 2. Moreover, it demonstrated strong neutralization capabilities with  $ND_{50}$  (neutralizing dose) values of 0.0783 µg/ml for human IL-13 and 0.04 µg/ml for cynomolgus IL-13, indicating its efficacy in inhibiting IL-13-induced TF-1 cell proliferation (where the  $ND_{50}$  value is the concentration of monoclonal antibody required to reduce TF-1 cell proliferation by 50%, in response to a set concentration of IL-13). Furthermore, the antibody effectively neutralized mammalian-expressed human IL-13 with an  $ND_{50}$  value of 0.037 µg/ml and a recombinant Q130 human IL-13 variant with an  $ND_{50}$  value of 0.110 µg/ml. The binding affinity of the antibody was measured by SPR and found to be 32, 270, and 61.2 pM for det-1 tagged human IL-13, human IL-13, and cynomolgus IL-13, respectively (EP1802658B1).

**Antibody First Published in:** PMID:

**Note on publication:** The original publication describes the generation and characterization of an anti-human IL-13 antibody and its derivatives, including its humanization.

## Product Form

**Size:** 100 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.